NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Announces Reverse Stock Split and Merger

Core Viewpoint - NLS Pharmaceutics Ltd. is undergoing a significant transition involving a reverse stock split and a merger with Kadimastem Ltd. to enhance its market position and expand its capabilities in developing therapies for rare and complex central nervous system disorders [1][2][3] Group 1: Reverse Stock Split - A reverse stock split is scheduled for October 31, 2025, consolidating every 10 shares of NLSP into 1 share [2] - The current stock price is $0.74, reflecting a recent decrease of 29.52% [2] - The new CUSIP number for shares post-merger and reverse split will be H5835A109 [3] Group 2: Merger with Kadimastem Ltd. - The merger with Kadimastem Ltd. will result in a name change to NewcelX Ltd. and a new symbol "NCEL" on the Nasdaq Capital Market [2] - This merger aims to expand NLS Pharmaceutics' capabilities in its specialized field [3] Group 3: Market Performance - NLSP's stock has fluctuated between a low of $0.74 and a high of $0.94 today, with a yearly peak of $4.74 [3] - The company's market capitalization is approximately $2.34 million, with a trading volume of 1,409,410 shares [3]